Navigation Links
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
Date:11/29/2007

U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for the use of lacosamide as adjunctive therapy in

the treatment of partial onset seizures in adults with epilepsy.

ATLANTA, Nov. 29 /PRNewswire/ -- UCB announced today that the U.S. Food and Drug Administration has accepted for filing the New Drug Application (NDA) for the use of lacosamide as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The application includes three lacosamide formulations -- tablets, syrup and an intravenous injection. The proposed trade name for lacosamide is Vimpat(TM).

"This filing is another step in support of UCB's epilepsy franchise and its long-term commitment to advancing treatment options for patients with epilepsy," said Iris Loew-Friedrich, MD, PhD, Global Head of Development, UCB.

The NDA for lacosamide in epilepsy is supported by data from three clinical trials with a total of approximately 1,300 adults with uncontrolled partial onset seizures, despite taking one to three antiepileptic drugs (AEDs). In these studies, significantly greater 50% responder rates and reductions in median seizure frequency were seen versus placebo. The most common adverse events of lacosamide (greater than or equal to 10%) reported in these trials included dizziness, headache, nausea and diplopia.

A similar filing made to the European Medicines Agency (EMEA) earlier this year for the use of lacosamide as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy, was accepted and is currently under review.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting 40 million people worldwide including 2.5 million people in the US. It is caused by abnormal, excessive electrical discharges of the nerve cells or neurons in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes and effective classification guides treatment and prognosis. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or significant adverse side effects secondary to medication highlighting the ongoing need for the development of new antiepileptic drugs.

About Lacosamide: Lacosamide has a novel and dual mode of action. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target-collapsin-response mediator protein-2 (CRMP-2).

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA (Monheim, Germany) is a member of the UCB Group.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB, Inc
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Guruji Mahendra ... 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... happiness. Mahendra Trivedi is known by over 250,000 people from over 40 different ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women’s Excellence now ... the most minimally invasive approaches. , Women who have had multiple vaginal births ... factors include surgery to the pelvic floor, connective tissue disorders, and obesity. Women ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd Hobgood , ... medical and surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, ... non-surgical alternative for reduction of fat below the chin (aka the “double chin”). ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/5/2016)... ... , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the Miami Marathon ... 2003. This year, he ran all 26.2 miles with a green 25-pound ShelterBox strapped ... Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson will strap ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- HemaFlo Therapeutics, Inc. announced today that the United States Patent ... covering the use of NephroFlow to treat acute kidney injury ... said, "We are pleased to secure our rights to such ... PhD, HemaFlo,s founder, said, "We are pleased to secure our ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ...
(Date:2/8/2016)... , Feb. 8, 2016  Dynatronics Corporation ... of advanced-technology medical devices and rehabilitation equipment for ... congratulates the Denver Broncos, football team for winning ... Cullimore Jr. , Chairman and Chief Executive Officer.  ... and we look forward to enhancing their athletic ...
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
Breaking Medicine Technology: